Olmesartan‐induced gastritis with no lower gastrointestinal symptoms: A case report [PDF]
DEN OpenA 74‐year‐old man with decreased appetite, weight, and heartburn was referred to our hospital. His medications included olmesartan. Esophagogastroduodenoscopy (EGD) revealed antral‐dominant erosive gastritis and nodular mucosa.
Satoshi Kosaka +2 more
doaj +3 more sources
Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study [PDF]
Cardiovascular Diabetology, 2011 Background Angiotensin II receptor blockers (ARBs), including olmesartan and candesartan, are widely used antihypertensive agents. Many clinical studies have demonstrated that ARBs have organ-protecting effects, e.g., cardioprotection, vasculoprotection ...
Nakayama Tomohiro +4 more
doaj +3 more sources
Effects of Allisartan on Uric Acid, Left Atrial, Left Ventricular, and Artery Stiffness in Mild‐to‐Moderate Essential Hypertension [PDF]
The Journal of Clinical HypertensionThis study aimed to explore the effects of allisartan in mild‐to‐moderate essential hypertension. This is a randomized, double‐blind, crossover design involving 98 patients with mild‐to‐moderate essential hypertension.
Yancui Sun +6 more
doaj +2 more sources
Olmesartan‐Associated Enteropathy: An Uncommon Cause of Chronic Diarrhea [PDF]
Clinical Case ReportsOlmesartan‐associated sprue‐like enteropathy is an uncommon side effect and should be considered as a differential diagnosis in patients who are on Olmesartan and presenting with chronic unexplained diarrhea.
Ahmed Sayedahmed +5 more
doaj +2 more sources
Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study [PDF]
The Korean Journal of Internal Medicine, 2019 Background/Aims Olmesartan, a widely used angiotensin II receptor blocker (ARB), has been linked to sprue-like enteropathy. No cases of olmesartan-associated enteropathy have been reported in Northeast Asia.
Seng Chan You +5 more
doaj +1 more source
Olmesartan-Induced Enteropathy [PDF]
Methodist DeBakey Cardiovascular Journal, 2016 Olmesartan-induced enteropathy mimics celiac disease clinically and pathologically. As in celiac disease, the pathologic findings are villous atrophy and increased intraepithelial lymphocytes. Clinical presentation of olmesartan-induced enteropathy includes diarrhea, weight loss, and nausea. In contrast to celiac disease, tissue transglutaminase is not
Abimbola, Adike +5 more
openaire +2 more sources
Anti-proliferative effect of olmesartan on Tenon's capsule fibroblasts [PDF]
International Journal of Ophthalmology, 2016 AIM: To evaluate the inhibitive effect of olmesartan to fibroblast proliferation and the anti-scarring effect in Tenon’s capsule, both in vitro and in vivo.
Xuan Wang +3 more
doaj +1 more source
Clinics, 2015 OBJECTIVES: Remote ischemic perconditioning is the newest technique used to lessen ischemia/reperfusion injury. However, its effect in hypertensive animals has not been investigated.
Xin Lu, Yan-Wen Bi, Ke-Biao Chen
doaj +1 more source
Olmesartan-Associated Enteropathy [PDF]
Baylor University Medical Center Proceedings, 2017 Olmesartan, an angiotensin-receptor blocker frequently prescribed for hypertension, has been commercially available since 2002. In 2012, olmesartan-associated enteropathy was described, and the Food and Drug Administration now requires a black-box warning for olmesartan regarding severe diarrhea.
Vivian S, Ebrahim +5 more
openaire +2 more sources
Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status. [PDF]
, 2017 Antihypertensive monotherapy is often insufficient to control blood pressure (BP). Several recent guidelines advocate for initial combination drug therapy in many patients. This meta-analysis of seven randomized, double-blind studies (N = 5888) evaluated
Bakris, George +3 more
core +1 more source